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Abstract 
Joseph John Thomson discovered and proved through a series of experiments the existence of 
electrons. His work earned him a Nobel Prize in 1906 and initiated the era of mass spectrometry 
(MS). In the intervening time, other researchers have also been awarded the Nobel Prize for 
significant advances in MS technology. The development of soft ionization techniques was 
central to the application of MS to large biological molecules and led to an unprecedented 
interest in the study of biomolecules such as proteins (proteomics), metabolites (metabolomics), 
carbohydrates (glycomics) and lipids (lipidomics), allowing a better understanding of the 
molecular underpinnings of health and disease. The interest in large molecules drove 
improvements in MS resolution and now the challenge is in data deconvolution, intelligent 
exploitation of heterogeneous data and interpretation, all of which can be ameliorated with a 
proposed IMass technology. We define IMass as a combination of mass spectrometry (MS) and 
artificial intelligence (AI) with each performing a specific role. IMass will offer advantages 
such as improving speed, sensitivity and analyses of large data that are presently not possible 
with MS alone. Here, we present an overview of the MS considering historical perspectives 
and applications, challenges as well as insightful highlights of IMass. 
HISTORICAL PERSPECTIVES OF MS   
Mass spectrometry (MS) is an analytical technique that ionizes chemical species and sorts 
the ions based on their mass-to-charge ratio (De Hoffmann & Stroobant, 2007; Sheynkman et 
al., 2016). By analyzing the ions, information including molecular mass, chemical structure 
and fragmentation pattern of a molecule is obtained (De Hoffmann & Stroobant, 2007; 
Lehmann, 2016). Although the pioneering work of MS has been attributed to Joseph John 
Thompson, history has shown that other scientists such as Eugen Goldstein (1886) and Johann 
Wilhelm Hittorf (1869) began such experiments long before him. Since then, several important 
events initiated by different scientists have taken place (Cooks et al., 2006; Danikiewicz, 2013; 
                                                IMass Time: the future, in future! 
3 
 
Fridriksson et al., 1999; Hurst et al., 1998; Karas & Hillenkamp, 1988; Kauppila et al., 2006; 
Salih et al., 1998; Veenstra, 1999; Wilkins et al., 1999), many of which are shown in Table 1. 
Most notable in the context of this review is the 2002 Nobel Prize to Fenn and Tanuka for their 
work on soft ionization methods, electrospray ionization (ESI) and matrix assisted laser 
desorption ionization (MALDI), which expanded the capability of MS to include large 
biological molecules. In ESI, a buffer of an analyte is dispersed by an electrospray into an 
aerosol. The aerosol undergoes repeated solvent evaporation, and as the electric field increases, 
offspring droplets are formed which split into multiply charged ions (Hoffmann & Stroobant, 
2001). MALDI on the other hand, involves the application of laser pulse to analyte-matrix 
crystals causing them to sublime into gaseous ions. The gaseous ions then migrate to the 
analyser under the influence of an electric field (Hoffmann & Stroobant, 2001). Surface 
enhanced laser desorption ionisation (SELDI) is a variant form of MALDI where proteins of 
interest bind to a surface before subsequent laser ionisation and MS analyses. The interaction 
with the surface can be specific to a protein/peptide and hence effective for pre-fractionation 
of protein mixtures (Hutchens & Yip, 1993; Poon, 2007).  
Mass analyzers  
As MS technology continued to evolve, there was a pressing need for instruments that 
improved the analyses of organic molecules in a more accurate and precise manner. 
Consequently, magnetic sector double focusing, time of flight (TOF), quadrupole and the 
Fourier transform ion cyclotron resonance (FT-ICR) mass analyzers were developed. Ernest 
Lawrence introduced the cyclotron in 1932 where charged particles were accelerated under 
magnetic and radiofrequency fields. After two decades, Hipple and his colleagues applied the 
cyclotron’s principle to design a mass analyzer with better trapping and detection called the 
Omegatron. In this technique, only ions with specific m/z were accelerated and was later called 
the ion cyclotron resonance (ICR) (Russell & Siuzdak, 2003). William E. Stephens developed 
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the TOF mass analyzer in 1946 where ions moved at different velocities towards a collector 
(Russell & Siuzdak, 2003). In the 1950s, Paul Wolfgang developed the quadrupole mass 
analyzer for which he received the Nobel Prize in 1989 (Paul, 1990). Here, an electric field 
triggered the formation of ions in a quadrupole. As the polarity was altered, the ions oscillated 
and those with specific m/z passed to the detector and were analyzed (Paul, 1990). 
Melvin Comisarow and Alan Marshall in 1974 further explained that accelerated ions 
generate currents as they hit the detector and that this current is Fourier transformed into a 
frequency spectrum, hence the name Fourier transform ion cyclotron resonance (FT-ICR) 
(Comisarow & Marshall, 1974). The FT-ICR is undoubtedly powerful and provides good 
resolving power and mass accuracy, but while it can operate in MS/MS mode it is not very 
sensitive due to lower pressure and hence poor collision efficiency of the collision cell 
(Makarov et al., 2006). These MS/MS experiments are completed very effectively using triple 
quadrupole MS technology. In it most classical mode, selected reaction monitoring (SRM), 
selected precursor ions pass through the first quadrupole and into the second quadrupole or 
collision cell where they are fragmented. The fragmented ions are resolved and directed to the 
detector for analysis. In some cases, the third quadruple is replaced with a linear ion trap (LIT), 
which allows further MS/MS experiments on the fragments (Makarov, 2000).  
The most recent innovation in MS is arguable the orbitrap, invented by Makarov. The 
orbitrap utilizes static electrostatic fields to cause the back and forth movement of ions around 
a spindle and the m/z ratios are obtained from harmonic axial oscillations. The axial motion of 
the ions generates currents which are detected while the accompanying signals undergoes 
Fourier transformation into a mass spectrum (Hardman & Makarov, 2003; Makarov, 2000; 
Makarov et al., 2006; Scigelova & Makarov, 2006). The Orbitrap has several advantages 
including: mass resolution of 240,000 FWHM at m/z 200; mass range of 50-6000 amu, large 
dynamic range, greater than 5000:1; and high mass accuracy of 1-3 ppm (Hu et al., 2005).  
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A plethora of hybrid mass spectrometers have been developed to extend the capability and 
functionality of instruments and include: quadrupoles in combination with TOF and orbitraps 
(Downard, 2007; Griffiths, 1997; Hardman & Makarov, 2003; Hevesy, 1948; Hu et al., 2005; 
Scigelova & Makarov, 2006; Thomson, 1906).  
 
INSERT TABLE 2 HERE 
 
The timeline of Nobel Prize awarded in MS technology field (Downard, 2007; Gault & 
McClenaghan, 2013; Griffiths, 1997; Hargittai, 2007; Hevesy, 1948; Konijnenberg, Butterer, 
& Sobott, 2013; Paul, 1990; Stahl, Steup, Karas, & Hillenkamp, 1991; Tanaka et al., 1988; 
Thomson, 1906) is shown in Table 3.  
INSERT TABLE 3 HERE 
Applications of MS 
MS technology was first used in gas analysis, while measuring stable isotopes of chemical 
elements and then applied to the analysis of complex hydrocarbon mixtures in petroleum 
fractions in the early 20th century. Early use of MS verified that positive and repeatable mass 
spectra can be obtained in MS analysis of organic molecules, enlightening researchers to 
elucidate the structure of organic compounds (Hsieh et al., 2015; Lehmann, 2016). From the 
mid-20th century, MS technology has been used in the life sciences and clinical medicine fields, 
for profiling and detecting complex macromolecules such as proteins, carbohydrates, lipids and 
metabolites (Aretz & Meierhofer, 2016; Blanksby & Mitchell, 2010). In fact, the MS 
technology has become the tool of choice in providing detailed information on how these 
biomolecules interact with each other during normal and diseased states (Hoffmann & 
Stroobant, 2001). Therefore, a larger part of this review will address the application of MS in 
three major fields of systems biology: proteomics, glycomics and lipidomics.
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1) Mass spectrometry in proteomics 
The proteome, introduced in 1994 (Wilkins et al., 1996), is defined as a 
collection of proteins expressed by the genome, cells and tissues at a given period or 
under a specified condition, and proteomics is the study of the large scale of proteins 
including their structure, functions and their role in health and diseases (Patterson & 
Aebersold, 2003). Proteins are abundant in mammalian cells (~2-4 million), occupying 
nearly half of the total cell mass and forming complex networks that control cell 
signalling, define cell function and interact with other molecules to manifest cell 
phenotype (Aebersold & Mann, 2016; Clancy & Hovig, 2014). Protein complexity is 
increased by a myriad of post-translational modification(s) (PTM) including: 
phosphorylation, ubiquitylation, glycosylation, sialylation, nitrosylation, lipidation, 
acetylation and methylation (Adua et al., 2017; Wang, 2016). For example, there are 
nearly 19,000 sites of ubiquitylation on almost 5,000 proteins (Kim et al., 2011; Larance 
& Lamond, 2015). Additionally, splice variants, protein stability/instability and 
dynamism, and transient protein interactions collectively make the protein more 
complex (Larance & Lamond, 2015; Mallick & Kuster, 2010).  
Many proteomics approaches, particularly those concerned with cell signalling 
and biomarker studies, are possible either via bottom up or top down MS analyses. In 
the bottom up approach, proteins are first digested with enzymes (e.g. trypsin) into 
peptides following which peptides are subjected to chromatographic separations. After 
ionisation and fragmentation, spectral analysis and structural assignments are 
performed by appropriate database matching (Hutchens & Yip, 1993; Karas et al., 1991; 
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Smith et al., 1991) (Figure 1). The top down approach aims to measure intact proteins 
(Aebersold & Mann, 2016; Liu et al., 2010; Patterson & Aebersold, 2003). 
 
INSERT FIGURE 1 HERE 
 
Both approaches have allowed studies on how proteins change in response to 
environmental influences or pathophysiological conditions (Shi et al., 2016). A typical 
illustration is the examination of peptides in type II diabetes mellitus (T2DM) patients 
and healthy controls (Meng et al., 2016). Briefly, serum samples were prepared from 
whole blood following which proteins were isolated and purified. After repeated 
washing of the supernatant in the presence of magnetic beads, the final samples were 
analysed on a MALDI-TOF-MS to generate MS peptide profiles. After data 
interpretation, amino acids of the candidate peptides were identified as being significant 
and potential biomarkers for T2DM (Wang et al., 2017).  
Similarly, MALDI-TOF-MS was used to identify serum peptides as potential 
biomarkers for colorectal cancer (Wang et al., 2017-In press). MALDI-TOF-MS was 
also used to profile ageing related proteins in the plasma (Lu et al., 2012). The study 
identified 44 peptides that were differentially expressed among the age groups and 
observed significant associations between age and three proteins: fibrinogen alpha 
(FGA), albumin (ALB) and apolipoprotein A-I (ApoA1). These proteins could be 
important biomarkers for ageing (Lu et al., 2012).  
In another study, SELDI-MS was used to profile peptides in the plasma of 
patients with ovarian cancer and age and gender-matched controls. With a sensitivity 
and specificity of 84% and 89% respectively, the authors detected protein peaks that 
were only expressed in the patients but not controls (Wu et al., 2006). 
Of late, it is becoming increasingly apparent that a single MS technology is not 
sufficient to comprehensively perform all proteomic measurements, especially for 
proteomics studies involving large populations (Gika et al., 2014; Patterson & 
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Aebersold, 2003). Coupling MS with separation techniques such as liquid 
chromatography (LC) and gas chromatography (GC) reduces the complexity of the 
sample by separating the proteins/peptides by time. For example, in a 2-year 
observational study, LC in tandem with a high resolution Orbitrap MS was used to 
profile peptides produced in acellular bronchoalveolar lavage (BAL) fluids of patients 
suspected to be suffering from lung cancer. After extensive interrogation of the LC-MS 
data and the literature, the researchers identified 133 differentially expressed proteins 
that could be potential biomarkers for lung cancer (Carvalho et al., 2017).  
For complex samples, the fragmentation pattern of the analytes is necessary to 
aid identification. Several MS/MS acquisition modes have been employed to capture 
and elucidate the complexity of the sample. One approach, data-dependant acquisition 
(DDA) involves preselecting the most intense ions and sending them sequentially to the 
collision cell, the resulting fragment ions are then analysed by the detector (Bauer et al., 
2014; Porter & Bereman, 2015). A limitation of this approach is that only the more 
abundant peptides are selected for MS/MS fragmentation, while an advantage is that 
the MS/MS pattern, or fragment ions, can be directly linked to the precursor ion. 
Another approach is data independent acquisition (DIA) where all the precursor ions at 
a given time are sent to the collision cell, or where the precursor ions within selected 
mass ranges are sequentially sent to the collision cell (Porter & Bereman, 2015). The 
advantage of this approach is more complete coverage of the peptide profile as all 
precursor ions are fragmented (Porter & Bereman, 2015). However, the data processing, 
or deconvolution of the data, is more complex as the relation between parent ion and 
MS/MS is lost.  
The DIA approach was employed to profile proteins in hepatitis B virus-
associated hepatocellular carcinoma (HCC) and non-tumour cells (Gao et al., 2017). 
They identified and quantified a total of 4,216 proteins of which 338 were differentially 
expressed between the groups. In addition, 191 and 147 proteins were up-regulated and 
down-regulated respectively, in tumour cells. Further, the study identified important 
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metabolic pathways that were altered in HCC including the pentose phosphate pathway 
(PPP), glycolysis, gluconeogenesis, fatty acid synthesis and β-oxidation as well as other 
metabolic enzymes including glucose-6 phosphate dehydrogenase (G6PD) and 
phosphoenolpyruvate carboxykinase (PCK) (Gao et al., 2017). Similarly, the DIA 
approach was applied to profile proteins in the saliva of nasopharyngeal carcinoma 
(NPC) and healthy controls. Among the 1,414 proteins identified, 29 were differential 
expressed (Luo et al., 2017).  
 MS technology has improved biomarker discovery; however, proteomics analyses 
and interpretation of the raw MS data would not have been possible without dedicated 
processing software and online resources. Examples of such are Census, 
BioworksBrowser (Meng et al., 2016), Mascot, SEQUEST (Elias, Haas, Faherty, & 
Gygi, 2005), COMPASS, MaxQuant and Skyline (Cifani et al., 2017) amongst others, 
all of which have enabled peptide identification and quantification. These web 
resources are supported by statistical packages such as Statistical Package for Social 
Sciences (SPSS) and the R Software for analysis while visualisation and annotation are 
also possible with the Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) (Huang et al., 2009).  
2) Mass spectrometry in metabolomics 
The metabolome refers to the collection of metabolites in cells, tissues and 
organs of an organism and a metabolite is defined as a substrate, an intermediate or a 
product of an enzyme catalysed biochemical reaction (Dunn et al., 2011; Mathew & 
Padmanaban, 2013; Tebani et al., 2016).  
Metabolites are abundant with 2,000 plus existing in mammals that range from 
50 to 1500 Da (Aretz & Meierhofer, 2016). Metabolites are important for the synthesis 
of adenosine triphosphate (ATP) and are key intermediates in cell signalling and 
regulation (Dunn et al., 2011). They exhibit different physicochemical properties such 
as solubility, half-life, molecular weight, acidity, basicity, hydrophobicity and 
hydrophilicity (Dunn et al., 2011). Moreover, unlike the transcriptome and the proteome 
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whose turn over occurs in minutes to hours, the synthesis and degradation of 
metabolites occur in seconds (Doerr, 2017).  
Compared to proteomics, metabolomics’ biological significance cannot be 
overemphasized. For example, unlike genes and proteins that can be influenced 
epigenetically and post-translationally respectively, metabolites are direct measures 
(substrates/products) of a biological activity and better linked with an individual’s 
phenotype (Patti et al., 2012). Additionally, they act as indicators of genetic and 
environmental change. As a result, information derived from metabolome is of several 
orders of magnitude greater than the genome, transcriptome and the proteome (Patti et 
al., 2012). 
Metabolomics refers to the system-wide study and analysis of the structure and 
function of a collection of metabolites and this can be achieved in two strategies (Li et 
al., 2016): targeted and non-targeted. The targeted approach involves measuring 
specific metabolites of interest and this is normally applied in pharmacologic research 
where the interest lies on therapeutic compounds. Untargeted metabolomics however, 
involves the measurement of the entire metabolome in a biological system (Patti et al., 
2012; Savolainen et al., 2015).  
Like proteomics, metabolomics analysis requires sophisticated analytical 
techniques that are accompanied by dedicated software for data handling and 
interpretation. MS has been the driver of modern metabolomics because of its ability to 
analyse complex metabolites with high performance (Ghaste et al., 2016). Usually, 
metabolomics profiling is performed using MS interfaced with a separation mode (GC, 
LC or capillary electrophoresis, CE) rather than MS alone (Savolainen et al., 2015; 
Zhang et al., 2016). Furthermore, for LC separations, samples are routinely separated 
using two columns, a reversed phase column to profile the non-polar metabolites and a 
hydrophilic interaction liquid chromatography (HILIC) column to capture the polar 
metabolites (Manaf et al., 2018-In press). Another approach used to optimally capture 
the metabolome, and which is also used in proteomics, is to use more than one MS 
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platform. For example, using both GC-MS and LC-MS or CE-MS to analyse the 
samples provides a more complete profile of the metabolome (González-Peña et al., 
2016; Psychogios et al., 2011).  
Recently, two platforms, GC-MS and nuclear magnetic resonance (NMR) were 
used to profile metabolites from the serum of patients with unstable angina (UA), ST-
elevation myocardial infarction (STEMI) and healthy controls. The study found 19 
unique metabolites that could be potential biomarkers for acute coronary syndrome (Ali 
et al., 2016). In another example, two complementary techniques, LC-QTOF-MS and 
GC-TOF-MS were used to examine urinary and blood metabolites in patients with 
obstructive sleep apnea, simple snorers and healthy controls. Here, 56 different 
metabolites including 4-, glycochenodeoxycholate-3-sulfate, arabinose, 
hydroxypentenoic acid, xanthine, isoleucine, serine, and xanthine, amongst others, 
were identified. Of the 56 metabolites, 21 were expressed in simple snorers and 31 in 
obstructive sleep apnea individuals. Interestingly, 24 of the detected metabolites were 
always higher or lower among the two groups when compared with controls, harnessing 
these metabolites can promote the diagnosis of polysomnography (PSG)-associated 
obstructive sleep apnea (Xu et al., 2016). Further, GC-MS was used to profile 
metabolites and examine abnormalities in the sera of traumatic brain injury patients 
with cognitive defects and without cognitive defects and healthy controls. They found 
nine metabolites including galactose, phenylalanine, linoleic acid, pyroglutamic acid, 
citric acid, palmitic acid, and 2, 3, 4-trihydroxybutyrate and arachidonic acids that were 
distinguishable among the three groups and this could advance the understanding on 
the mechanisms that underpin cognitive impairment (Yi et al., 2016). In another study, 
LC-MS was used to profile metabolites in the urine of patients with esophageal 
squamous cell carcinoma and healthy controls. Here, 19 of the 83 identified metabolites 
were potential biomarkers for esophageal squamous cell carcinoma diagnosis. Further, 
LC-MS helped to reveal purine and pyrimidine alterations in esophageal squamous cell 
carcinoma (Xu et al., 2016). 
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While providing insights on the biomarker potential of specific metabolites, this 
section cannot end without recognising databases or platforms that support data 
handling and interpretation. Examples are MetaboAnalyst (Xia et al., 2012; Xia et al., 
2015), MeltDB (Costa et al., 2015; Kessler et al., 2013) and Metabolite Set Enrichment 
Analysis (MSEA) (Xia & Wishart, 2010). Others include HMDB,’ ‘Metlin,’ ‘XCMS’ 
and ‘MzMine (Pluskal et al., 2010). 
3) Mass spectrometry in glycomics 
The glycome comprises a collection of glycan structures in the cell. The glycan 
structure is complex, and it is made up of least ten monosaccharides that join each other 
stereochemically (Igl et al., 2011). They are dynamic and post-translationally bind to 
proteins in glycosylation (Zoldoš et al., 2013; Sebastian et al., 2016, Liu et al., 2018; 
Liu et al., 2018b). Glycosylation affects nearly 8,000 proteins altering their function, 
secretion, folding, degradation and clearance (Adua et al., 2017; Fiedler & Simons, 
1995; Helenius & Aebi, 2001, 2004; PARODI, 2000). Thus far, four main types of 
glycans are recognized and these are N-glycans that bind to asparagine (Asn) residues 
in Asn-X-threonine [Thr]/Serine [Ser], sequon; O-glycans that bind to Ser and Thr 
residues; glycosaminoglycans (GAGs) that attach to proteins in a sequon (Gly)-X-Gly 
(X≠proline) and C-glycans that bind to peptides via carbon-carbon bonds in a 
tryptophan (Trp)-X-X-Trp sequon (X≠proline). While recognizing all these glycan 
types, this review will centre on N-glycans (Adua et al., 2017; Wang, 2016).  
N-glycosylation is an ordered event that occur via the interplay of glycosidases 
and glycotransferases as they transverse the secretory pathway. This process is not 
template driven, and not directly encoded by genes. As such, N-glycans are products of 
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an extensive protein modification whose structures are many orders of magnitude more 
complex than the proteins (Adua et al., 2017; Wang, 2016; Yu et al., 2016). N-glycans 
regulate and control cellular function as well as an underlying disease (Ge et al., 2018; 
Hebert & Molinari, 2007; Liu et al., 2018a; Russell et al., 2018). Therefore, the study 
of glycan structure and function (glycomics) has been the focus of a cutting-edge 
research in the post-genomics era. N-glycans are stable, up to a year and only change 
in response to external stimuli. It is therefore not unexpected that N-glycans are altered 
in many chronic diseases such as cancer (Bones et al., 2010; Lau & Dennis, 2008; Llop 
et al., 2016; Mereiter et al., 2016), diabetes (Itoh et al., 2007; Testa et al., 2015), 
metabolic syndrome (Lu et al., 2011; McLachlan et al., 2016), hypertension (Wang et 
al., 2016), Alzheimer’s (Gizaw et al., 2017) and Parkinson’s disease (Russell et al., 
2017).  
Like proteomics, the successful application of glycomics in many of these 
chronic diseases have been powered by MS. MS allows structural assignments of 
constituent monosaccharides within a complex oligosaccharide, and in conjunction 
with exoglycosidase digestions, the full structural and linkage analysis are made 
(Figure 2). It is however important to realize the type of N-glycans under investigation 
since acidic and neutral glycans require distinct ways of analyses. While a 2, 
5-dihydroxybenzoic acid (2, 5-DHB) matrix in positive ion mode is sufficient to ionize 
neutral glycans and generate a good MS spectrum, acidic glycans are better ionized in 
a negative ion mode with either 2, 4, 6-trihydroxyacetophenone (THAP) or 6-aza-2-
thiothymine matrices (Snovida & Perreault, 2007; Wada et al., 2007).  
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INSERT FIGURE 2 HERE 
Employing the state-of-the-art MALDI-TOF-MS and hydrophilic interaction 
liquid chromatography (HILIC) technology, a study investigated the N-glycosylation 
and IgG profiles in the plasma of mothers and the umbilical cord of their newborns 
(Jansen et al., 2016). Briefly, IgG was isolated from the plasma with IgG Fc beads, after 
which 20µL was transferred onto a 96 well plate. Proceeding this were multiple washing 
steps, while the eluent was transferred onto another plate and centrifuged. IgG N-
glycans and plasma N-glycans were released in a stepwise manner using peptide N-
glycase F (PNGase F) in phosphate buffered saline (PBS). This was followed by 
esterification while the samples were separated and purified on HILIC. The purified 
and esterified samples were added to an MTP anchor Chip 800/384 MALDI plate and 
measured on MALDI-TOF-MS. The generated spectrum was then processed and 
analysed using MassyTools software. Utilising this method, the authors quantified 37 
IgG N-glycans and 45 total plasma N-glycans in the plasma of mothers and their 
newborns. Additionally, the study observed a reduced sialylation, and galactosylation 
and an increased fucosylation in plasma of the umbilical cord (Jansen et al., 2016).  
In another study involving the simultaneous application of four methods for 
analysing immunoglobulin G (IgG) N-glycans, it was shown that MS methods 
(MALDI-TOF-MS and nanoLC-ESI-MS) when compared to UPLC combined with 
fluorescence detection and capillary gel electrophoresis with laser induced florescence 
detection, had a higher throughput, was suitable for site specific glycosylation and 
provided detailed structural information with highly sensitivity (Huffman et al., 2014). 
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In glycomics, the software supports for data handling and interpretation include: 
GlycoBase (Hizal et al., 2014), GlycoExtractor (Artemenko et al., 2010), 
EUROCarbDB (von der Lieth et al., 2011), GLYCOSCIENCE.de (Lütteke et al., 2006), 
GlycomeDB (Ranzinger et al., 2011), MassyTools (Jansen et al., 2015) and 
GlycoWorkBench (Ceroni et al., 2008; Yu et al., 2013). 
4) Mass spectrometry in lipidomics 
The lipidome comprises a collection of lipids in the cells of an organism (Sandra 
& Sandra, 2013; Shevchenko & Simons, 2010). Lipids are abundant, and it is estimated 
that the eukaryotic cell comprises 10,000 to 100,000 lipid species from different lipid 
classes (Van Meer et al., 2008). These lipid classes are sphingolipids [e.g. sphingosine 
phosphate and ceramides (CER)] and glycerophospholipids [e.g. phosphatidylcholines 
(PC), lyso-phosphatidylcholines (LPC), phosphatidylserines (PSs) and 
phosphatidylethanolamines (PEs)], glycerolipids [(monoacylglycerols (MAGs), 
diacylglycerols (DAGs) and triacylglycerols (TAGs)] (Shevchenko & Simons, 2010; 
Wenk et al., 2015). Taken together, these lipids make up the matrix of the cell membrane 
and are responsible for many cellular processes including membrane trafficking, 
biological reproduction, cell division, cellular architecture, signalling, cell-cell 
interaction, efficient fuelling and energy schemes for the cell (German et al., 2007; 
Kontush & Chapman, 2010; Van Meer et al., 2008). Also, lipids are responsible for 
maintaining subcellular compartmentalization, generation of 1st and 2nd messengers 
during signal transduction and for ensuring a balance in electrochemical gradient (Hu 
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et al., 2009; Rai & Bhatnagar, 2017).  
Lipidomics refers to the system-wide study of lipids including their structures, 
regulation and function within the cell (Blanksby & Mitchell, 2010; Schwudke et al., 
2011). Introduced in 2003, lipidomics has been a frontier in recent research owing to 
their agricultural, pharmaceutical and clinical relevance (Wenk, 2005). Like proteomics, 
lipidomics analysis can be achieved by two main strategies: targeted and non-targeted 
lipidomics. While targeted lipidomics is restricted to identifying and quantifying known 
single lipid species using specific methods, non-targeted lipidomics on the other hand, 
relies on appropriate methods for the simultaneous identification and relative 
quantification of all lipids in a system (Sethi & Brietzke, 2016).  
Lipidomics analysis is challenging and regardless of the strategy employed, a 
powerful analytical tool is required. GC with flame ionization detection (FID) was 
widely used, and in fact, is still used for separating targeted well identified lipids such 
as the fatty acids because it is relatively cheap and simple to operate (Wenger, 2014). 
NMR has emerged as a useful tool because it can complete analysis within a short 
analytical run and importantly, did not require extensive sample pre-separation prior to 
detection. However, NMR can only detect the most abundant lipid species/metabolite 
within the sample (Gika et al., 2014). 
However, MS based techniques are superior both in coverage and identification. 
In addition to the already mentioned MS techniques for proteomics and glycomics, 
lipidomics can also be performed using MALDI-FT-ICR-MS (Stübiger et al., 2012). 
However, regardless of the technique employed, MS characterizes lipid species in two 
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ways. The first stage involves the determination of the intact mass of the molecules 
while the second involves collision of lipid ions with inert gases followed by 
dissociation into structural fragments. Comprehensive information such as 
classification, nomenclature and identification are obtained with the help of online 
resources such as the LIPID maps, Lipid Profiler (Ejsing et al., 2006), Lipid Inspector 
(Schwudke et al., 2006), LipidXplorer and Lipid Data Analyser (Hartler et al., 2011).  
Taken together, advances in MS technology and the accompanying software 
have revealed the role of lipids in various chronic conditions. For example, a study 
profiled lipid in the plasma of early stage cancer patients and individuals with benign 
breast disease (Chen et al., 2016). Briefly, lipids were isolated from plasma and 
centrifuged. Following this was the addition of internal standards and proceeded by 
injection into the LC system. Lipid profiling was then accomplished by LC-ESI-
MS/MS while data analysis was performed using Applied Biosystems Analyst. With 
this technology, the study was able to quantify 15 lipid species that could be potential 
biomarkers for breast cancer (Chen et al., 2016). In another study, the MALDI-TOF- 
MS technique was used to quantify 157 lipid species in plasma, 171 in high density 
lipoprotein cholesterol (HDL), 182 in low density lipoprotein (LDL) and 148 in very 
low density lipoproteins (VLDL)(Serna et al., 2015). 
 
INSERT FIGURE 3 HERE 
 
Similarly, while performing a global lipidomics profiling in prostate cancer 
(PCa) and benign prostate hyperplasia (BPH) patients using LC-MS, a total of 350 lipid 
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species comprising 6 cholesterol ester (CE), 7 DAG, 9 hexosylceramide (HexCer), 24 
free fatty acids, 10 Cer, 10 LPE and 10 LPC, amongst others, were identified, all of 
which could be potential biomarkers for prostate cancer (Li et al., 2016). Another study 
combined LC-ESI-SRM and MALDI-QIT-TOF-MS/MS to conduct a targeted 
lipidomics analyses in 13 patients with familiar combined hyperlipidaemia (FCH) and 
found many significant associations between atherogenic LPC species and VLDL 
(Figure 3) (Stübiger et al., 2012). Similarly, a targeted lipidomics profiling in the sera 
of chronic hepatitis B (CHB) patients, hepatitis B virus associated cirrhosis (HCV) and 
hepatocarcinoma (HCC) using UPLC-MS and identified 140 lipid species which could 
be potential biomarkers (Wu et al., 2017). 
While MS technology has been a propeller for many “OMICS” studies, there 
are some prevailing challenges. Therefore, the remainder of this manuscript is dedicated 
to revealing these challenges and highlighting the need for innovation. 
Summary of existing problems in MS 
Having provided a comprehensive review of the MS technology and its 
applications, there is the need to recap the main limitations that characterize this 
technology. For example, the MALDI-TOF-MS is limited by signal suppression effects 
and narrow dynamic ranges of detectors (Poon, 2007). These problem seem to be 
ameliorated with the advent of the SELDI-TOF MS, however, SELDI-TOF has the 
following limitations: poor resolution for large proteins (e.g. markers with molecular 
weight > 20kDa); enormous amount of time required for purifying all significant 
SELDI peaks; lack of reproducibility; 4) serum/plasma proteins < μg/ml cannot be 
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detected; susceptibility to identifying false-significant biomarkers (Poon, 2007). These 
challenges have largely been addressed by exploring multiple hyphenated MS 
platforms and other techniques (e.g. NMR). Although these complementary approaches 
have improved sensitivity, accuracy, run times and analytical coverage, there are still 
problems relating to identification of low abundant analytes, sequencing speed (e.g. 
proteomics), deconvolution, handling and performing large data analysis, inadequate 
information from spectra to produce sequence identifications, data standardization and 
data fusion across multiple analytical platforms (Gika et al., 2014; Liu et al., 2010).  
Given the prevailing challenges, it is time to shift towards extreme automation 
powered by information technology (IT) or computer science. IT promises to solve 
many complex problems using conventional algorithms and neural networks. Moreover, 
IT can enable intelligent exploitation of heterogeneous data, translational research and 
provide solution for implantation science (Combi, 2017; Özdemir & Hekim, 2018). 
While it is beyond the scope of this review to discuss in detail these concepts, a brief 
introduction and definition of terms will be necessary. 
IMass  
IMass is a term coined by us that incorporates traditional MS technology and 
Artificial intelligence (AI). Here, experimental methods are accomplished with MS 
while AI performs data processing and analysis. The IMass will help to answer complex 
scientific questions and generate ideas that were not previously possible with MS 
technology alone.  
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1) Information technology 
     IT is a generic term that encompasses information management, retrieval, data 
manipulation and processing. Information systems and application software are 
designed, exploited, installed and carried out by computer science and communication 
technology. IT includes sensor technology, computer technology, AI technology, 
communication technology and internet technology. 
Nowadays, IT has improved tremendously. Internet of Things (IoT) and cloud 
computing are typical representations (Özdemir & Hekim, 2018). IoT Internet of things 
are wireless connected network of objects or devices that interact with each other via 
embedded systems and ubiquitous intelligence (Xia et al., 2012). IoT is an important 
part of the new generation IT, changing information and communication based on 
Internet and extending the user sides to stereo dimension. By using information sensing 
devices including radio frequency identification (RFID) infrared sensors, global 
positioning system (GPS), laser scanner amongst others, internet of things is able to 
connect relayed events according to agreed protocols that in turn facilitate the 
identification, location, monitoring and management of objects (Kopetz, 2011; Sun, 
Song et al., 2016; Weber & Weber, 2010; Xia et al., 2012). 
    Cloud computing is defined as an internet-based computing that allows the storage 
and sharing of data and resources with other computers and devices. It shares 
characteristics with grid computing, parallel computing and utility computing 
(Armbrust et al., 2010; Buyya et al., 2009; Dikaiakos et al., 2009). Multiple PCs with 
relatively low cost are integrated to a system with powerful computing capacity. Results 
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of the system are then fedback to end users through advanced business model such as 
SaaS, PaaS, IaaS and MSP (Lenk et al., 2009).  
2) Artificial intelligence  
AI is an important branch of computer science. It was officially put forward by 
McCarthy in Dartmouth Society in 1956 as “artificial system with certain degree of 
intelligent behavior that applies studies in human intelligence activity (Hamet & 
Tremblay, 2017; Nilsson, 2014; Patel et al., 2009; Russell & Norvig, 1995)”. AI has 
undergone many developmental stages since the 1950s. Alan Turing proposed the 
theoretical model which established the theoretical foundation of modern computers, 
and the famous Turing guidelines, which has been the most important standard of 
intelligent machine (Castelfranchi, 2013).  The era of AI gave rise to the idea that 
instead of programming computers to perform tasks, they could teach themselves or 
learn to perform tasks without being explicitly programmed to do so. This concept was 
later referred to as machine learning (ML). ML applies set of rules called algorithms to 
solve a problem and it easily adapts to changes in data, scalable and efficient compared 
to those programmed by humans. An extension of ML is deep learning (DL) which is 
based on data representations and designed to learn from an input data and apply to 
other data (Cohen & Feigenbaum, 2014; Nilsson, 2014). 
    Knowledge-based expert systems have been developing rapidly and its application 
range has provided enormous benefits across all human fields. Nowadays, AI has 
advanced into large-scale distributed expert cooperative systems, parallel deduction and 
multiple expert system development tools (Wenger, 2014). The year 2016 was known 
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as “The primary era of AI” because of massive developments of AI which was also 
characterized by several landmark events. For instance, AI program AlphaGo designed 
by Google DeepMind defeated human Go champion Lee Chang-ho in March 2016. 
IBM WATSON HealthCare passed the United States Medical Licensing Examination 
(USMLE) and got medical license in the same year. Moreover, the first self-driving car 
designed by EasyMile (France) and Citymobil2 (European Union) was tested in 2016 
(Figure 4). With the rapid advances in software programming, electronic speed and 
capacity, it is obvious that IT will not only impact society and daily life but also, the 
intelligence of computers will someday surpass that of humans (Hamet & Tremblay, 
2017). However, the compelling question is how the concepts and applications of AI or 
IoT can be impactful in MS and OMICS analysis?  
3) Application of IMass to MS 
The MS systems resulted in an increased operational complexity and overwhelming 
experimental data were obtained from a single analysis. This increasing and enormous 
amount of information demanded an optimization of the instrument’s operational 
conditions to acquire the most significant data (Place, 1995; Wong, 1984). This 
triggered the need to incorporate AI to MS instrumentation during the early 1970s and 
several developments have followed over the years (Figure 4). The first-generation 
intelligent software, alongside AI algorithms including Bayesian algorithm, Vector 
Support Machine, Decision Tree, Random Forest and Artificial Neural Network were 
all developed to support MS (Kondrat et al., 1978; RA et al., 1979). Expect system, 
described as computer program that houses a high quality and specialized knowledge 
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to solve complex problems was developed. It was designed to build upon the problem-
solving abilities of human experts and in some cases, apply complex reasoning to solve 
problems that is beyond the capabilities of human experts. Neural networks that mimic 
the pattern-recognition and parallel processing of human experts were also developed 
(Place, 1995; Wong, 1984).  
Over the years, it has been shown that AI has enormous potential to transform the 
efficiency of MS. The incorporation of MS to AI and expert system, not only will it 
adapt and respond to situations quickly, but also it will utilize the power of reasoning 
and inference to effectively perform tasks and interpret correct the data to meet the 
researcher’s experimental targets. AI was applied for tuning the triple quadrupole mass 
spectrometer (TQMS). This was to allow analytical chemists to tune the instrument 
over small mass ranges to increase the sensitivity for each ion. Here, two approaches 
were employed; an expert system and algorithmic approach. It was shown that AI 
powered tuning increased the sensitivity, was faster compared to manual tuning 
methods which is time consuming. Further, while analysing 12 sulphur compounds 
using TQMS, it was shown that more time was required by a human expert to manually 
tune for each parent/daughter ion compared to an AI tuning system (Brand and Wong, 
1986). 
For example, in 1990, expert system alongside Bayesian algorithm and AI 
software were employed to detect low resolution mass spectra (Scott, 1991). The expert 
system obtained a canonical representation of structures and a new heuristic for 
incorporating constraints of the mass spectrum (Sridhar et al., 1991). The MS combined 
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with AI and expert system were utilized for optimizing and controlling MS performance, 
detector signal collection as the function of m/z and improved overall data analysis.  
With different combination metrics, AI can transform the information extracted 
from the MS, interpret data from spectra and present such data in a visual and symbolic 
form.  It can be useful for identifying pre-analytical and analytical errors; AI can be 
applied to assess the performance of an MS instrument and can reveal whether the 
instrument’s performance is within algorithmically pre-determined specification; AI 
can enable the prediction of protein complexes and can provide machine learning 
algorithms such as in protein-protein interactions to reveal therapeutic targets (Hamet 
& Tremblay, 2017); Stabilization of spectrogram is the consistency of spectrograms of 
repeated experiments from the same sample. For MS, spectrograms of repeated 
experiments are usually unidentical, with relatively large coefficient of variation 
(French et al., 2014; Muddiman & Oberg, 2005; Ramakrishnan, Nair, & Rangiah, 2016). 
Data analysis of MS belong to multi-index evaluation system, characteristics of each 
index are different, and the dimensions differ by several orders of magnitude (Du et al., 
2016; Edmands et al., 2014; Hamm et al., 2012). Because of variation in the indices, 
there is a possibility of over-highlighting some while weakening others, especially 
those with relatively smaller numbers. However, with the higher computational power 
and the higher statistical strengths by AI, these problems can be solved (Du et al., 2016; 
Edmands et al., 2014; Hamm et al., 2012; Liao et al., 2014); Resolution of spectrum 
library is the ability to differentiate one spectral peak from another. Resolution of 
spectrum library of traditional MS is low, not only because of the limited computing 
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power to support high resolution and high accuracy, but also because only few 
spectrograms are generated in a single-instrument model. For example, traditional MS 
technology has been applied on microorganism identification studies (Carbonnelle et 
al., 2011; Seng et al., 2010). However, the results are not always consistent or 
reproducible and often unstable, as well as variations that cannot be accepted. By 
incorporating AI technology, IMass will be able to overcome these shortcomings and 
produce more stable results with less variation. For example, enabled by artificial neural 
network analysis of the mass spectra, streptomycetes was identified it was shown to be 
rapid, reliable and cost-effective (Howells et al., 1992; Chun, 1993).  
Over the years, other significant improvements have been made. Bayesian 
algorithm was introduced to the protein search engine to identify protein from protein 
databases by MS data mapping (Zhang et al., 2000). The vector machine was applied 
to classify peptide MS/MS spectra and SEQUEST score (Anderson, 2003). In 2004, 
Random Forest, also called decision forest, developed to standardize the mass spectra 
and for sample classification (Satten et al., 2004; Tong et al., 2004).  
INSERT FIGURE 4 HERE 
4) IMASS and Big Data analysis 
Thus far, research has advanced and multi-OMICS studies involving large 
population are increasing. Consequently, there is the influx of Big Data or large 
“OMICS-based” datasets that are often characterised by large volumes, variety, veracity, 
valorisation and velocity (Özdemir & Hekim, 2018). Moreover, Big Data is becoming 
complex comprising demographic, biomedical signals, genetic data, and clinical 
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pathways (Combi, 2017). Additional sources of challenge for OMICS analysis are 
consequence of poor experimental design, low signal-to noise ratio and high analytical 
variance. Other challenges also relate to real-time data gathering, mining storage, 
predictive data analytics, and visualization. The full potential of such Big Data can only 
be harnessed after real-time data analysis and cannot be possible with the old scientific 
practices. AI and IoT can be employed to translate Big Data into knowledge-based 
innovations (Özdemir & Hekim, 2018). For example, it can support the translation of 
science into a more decision-based tasks such as patient stratification, disease 
prediction, diagnosis, and therapy (Combi, 2017; McCudden, 2017). Also, ML methods 
can draw meaningful conclusions from relatively small data; transforming data into 
visualizable images (Grapov et al., 2018). ML methods may provide efficient 
integration of omics data integration, thereby amplifying significant biological variants 
and enabling full interrogation of biological systems. 
The size and complexity of data put a significant pressure on computers for analysis. 
IMass supported by cloud computing (Hoopmann & Moritz, 2013; Mohammed et al., 
2012; Schadt et al., 2010), makes it more suitable to analyze complex and large sample 
data. Cloud computing resources can be expanded and can provide additional power 
for data analysis, facilitate sharing of large data (Hoopmann & Moritz, 2013; 
Mohammed et al., 2012; Schadt et al., 2010). This will be an important step towards 
MS innovation; presently, comparing MS data to medical reference libraries will 
require data to be inputted manually (Cho et al., 2015; Schilling et al., 2011), which is 
often time consuming, labor intensive and less accurate. IMass can be connected to 
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medical and biological components information libraries directly, data can be combined, 
shared and stored for high throughput analysis. This innovation can significantly save 
time, energy and at the same time, increase accuracy.  
However, the main challenge for IMASS is that OMICS data are not amenable to 
certain assumptions of DL. As a result, domain specific approaches are usually required 
to deal with unrelated biological variance. In the context of protein-protein interaction, 
it will be challenging to represent peptide and protein in a meaningful way. Advanced 
studies will be required to ascertain novel ways to represent protein sequence 
information. Moreover, high-quality data, large amount of correctly labelled training 
data and high parameter neural networks will be required for IMASS and achieving this 
is expensive and time consuming. Further, IMASS is complex and understanding 
specific neural networks and interpreting models will be challenging for amateur 
researchers. In addition, how to apply or use deep learning methods to yield a more 
realistic model and how to employ the estimation method to develop the prior 
knowledge of the deep neural network is can be a challenging task. Nonetheless, 
IMASS will be highly relevant in the pursuit of translating MS based research into 
clinical diagnosis and prognosis of diseases.  
Conclusion and future directions  
It should be clear to readers by now that the advent of the MS technology has 
revolutionized medical research to a larger degree. It has provided an insight on the 
molecular intricacies that underlie many chronic diseases and has made it possible to 
perform large scale “OMICS” analyses. All the application of MS technology for 
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population-based studies cited in this review have mainly focused on single OMICS 
data. However, it is about time that scientists shift focus from single OMICS to 
integrated or multiple OMICS data. This has become necessary because the molecular 
complexities associated with many diseases cannot be unraveled with just a single 
“OMIC” data (Hasin et al., 2017). Additionally, single OMICS analysis only provides 
correlations between traits and diseases with limited information on causative changes. 
In theory, beside the central dogma for DNA, RNA and proteins, the compelling 
question that is worth asking is what happens to the regulation of lipids and sugars and 
their glycosylation and how they are involved in health and diseases? Is there a para-
central dogma for encoding these functions? For practice, integration of different 
OMICS data will promote a comprehensive understanding on the flow of information 
that underpins chronic diseases (Hasin et al., 2017). For example, one study used 
genomics and glycomics data to show that hepatocyte nuclear factor alpha (HNF1α) is 
the master regular of fucosylation (Lauc et al., 2010). Similarly, another study 
combined glycomics and lipidomics data to shed light on the association between 
glycans and lipids in four European populations. Further, this study provided 
information on the interactive metabolic pathways that exist between glycans and lipids 
(Igl et al., 2011).  
While the MS technology has been pivotal in medical research, it has been limited 
in certain aspects. In theory, beside the central dogma for DNA, RNA and Proteins, 
what happens to the regulation of lipids and sugars and their glycosylation? Is there a 
para-central dogma for encoding these functions? In practice, from the past years to 
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date, then towards the future, the goals for MS technology must change from high 
resolution and high sensitivity to high stability and high repeatability, from focusing on 
single peaks to multiple peaks within a complex spectrogram, and from solving simple 
questions to solving more complex ones. Actualizing these demands require some 
innovations to the present MS technology. The incorporation of MS with AI is highly 
feasible and have broad prospects. For instance, incorporating MS technology with AI 
system platforms like AliCloud and IBM WATSON is such a great opportunity for 
researchers using MS to work out experimental data and use related algorithms 
exploited by AI technology to store and perform complex data analysis and processing. 
This is what researchers are expecting, and exactly what we are continuously working 
hard on and hoping it will come into fruition rather sooner than envisaged.  
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Abbreviations 
 
A-I    Apolipoprotein 
AI    Artificial intelligence  
ALB    Albumin  
ATP    Adenosine triphosphate  
CE    Capillary electrophoresis  
DAG    Diacylglycerols 
DAVID   Database for Annotation, Visualisation and Integrated Discovery 
DDA    Data-dependant acquisition 
DHB    Dihydroxybenzoic acid  
DIA    Data independent acquisition  
ESI    Electrospray ionization  
FGA    Fibrinogen alpha  
FID    Flame ionization detection  
FT-ICR   Fourier transform ion cyclotron resonance  
G6PD    Glucose-6 phosphate dehydrogenase  
GC    Gas chromatography  
GPS    Global positioning system 
HDL    High density lipoprotein cholesterol  
HILIC   Hydrophilic interaction liquid chromatography 
ICR    Ion cyclotron resonance  
IoT    Internet of things 
IT    Information technology 
LC    Liquid chromatography 
LIT    Linear ion trap  
LPC    Lyso-phosphatidylcholines 
MAG    Monoacylglycerols 
MALDI   Matrix assisted laser desorption ionization  
ML    Machine learning 
MS    Mass spectrometry  
NMR    Nuclear magnetic resonance  
NPC    Nasopharyngeal carcinoma  
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PC    Phosphatidylcholines  
PCK    Phosphoenolpyruvate carboxykinase  
PE    Phosphatidylethanolamine  
PPP    Pentose phosphate pathway 
PS    Phosphatidylserine  
PTM    Post-translational modification 
RFID    Radio frequency identification 
SELDI   Surface enhanced laser desorption ionisation  
SPSS    Statistical Package for Social Sciences  
SRM    Selected reaction monitoring  
T2DM   Type II diabetes mellitus  
TAG    Triacylglycerol  
TOF    Time of flight  
UPLC    Ultra-performance liquid chromatography  
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Table 1. Timeline of important events in development of MS technology 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time Event           
1886 E. Goldstein observes canal rays        
1897 W. Wien demonstrates that canal rays can be deflected using strong electric and magnetic fields  
 J.J Thompson measures the mass-to-charge ratio of electrons      
1901 W. Kaufmann uses a mass spectrometer to measure the relativistic mass increase of electrons  
1905 J.J. Thompson begins the study of positive rays       
1913 J.J. Thompson is able to separate particles of different mass-to-charge ratios    
1919 F. Aston constructs the first velocity focussing MS with mass resolution of 130    
1931 E.O. Lawrence invents the cyclotron        
1934 J. Mattauch and R. Herzog develop the double-focussing MS      
1936 A.J Dempster develops the spark ionisation source       
1937 F. Aston constructs a mass spectrograph with resolution of 2000     
1942 E.O. Lawrence develops the cyclotron for uranium isotope separation     
1943 Westinghouse markets its MS and proclaims it to be " A new electronic method for fast, accurate gas analysis" 
1946 William Stephens ? presents the concept of a time-of-flight MS      
1954 A.J.C. Nicholson proposes a hydrogen transfer reaction that will come to be known as   
 the McLafferty rearrangement         
1959 Researchers at Dow Chemical interface a gas chromatograph to a MS     
1964 British MS society establishes as first dedicated MS society. It holds its first meeting in 1965 in London  
1966 F.H. Field and M.S.B. Munson develop chemical ionisation      
1968 M. Dole develops electrospray ionisation       
1969 H.D. Beckey develops field desorption        
1974 M.B. Comisarow and A.G. Marshall develop Fourier Transform Ion Cyclotron Resonance MS   
1976 R. MacFarlane et al., develop plasma desorption MS      
1984 J.B. Fenn et al., use electrospray to ionize biomolecules      
1985 F. Hillenkamp et al., describe and coin the term matrix-assisted laser desorption ionization   
1987 K. Tanaka uses the "ultra-fine metal plus liquid matrix method" to ionize intact proteins   
1999 A. Makarov presents the Orbitrap MS        
2004 Z. Takats et al., develop the Desorption Electrospray Ionisation (DESI) method    
2004 D.F Hunt et al., develop Electron Transfer Dissociation (ETD) method     
2005 R.B. Cody and J.A Laramee develop the Direct Analysis in Real Time (DART) ion source   
Table 2: Timeline of Nobel Prize awarded in MS technology field 
 
Time 
 
Event 
1906 J.J. Thomson is awarded the Nobel Prize in Physics “in recognition of the great merits of 
his theoretical and experimental investigations on the conduction of electricity by gases” 
1922 F. Aston is awarded the Nobel Prize in Chemistry “for his discovery, by means of his MS, 
of isotopes, in a large number of non-radioactive elements, and for his enunciation of the 
whole-number rule” 
1939 E.O. Lawrence is awarded the Nobel Prize in Physics for the cyclotron 
1989 W. Paul is awarded the Nobel Prize in Physics “for the development of the ion trap 
technique” 
2002 J.B. Fenn and K. Tanaka are awarded the Nobel Prize in Chemistry “for the development 
of soft desorption ionization methods for MS analyses of biological macro-molecules” 
 
 
